The content on this site is intended for healthcare professionals only
Dr Ravandi talks to ecancertv about his highlights of ASH 2016.
He discusses his interest in acute myeloid leukaemia (AML), leukaemogenesis, the use of monoclonal antibody-based therapies, ALL, CLL, minimal residual disease monitoring and where he sees research heading in the future.
ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Advancements in paediatric Acute lymphoblastic leukemia management
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas
EHA 2024: Multiple myeloma roundup
Best practice in HRRm testing in patients with metastatic prostate cancer
Multiple myeloma in a resource constrained setting
